


This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

**1. (Currently amended)**

An epothilone compound of formula I,



in which

$R^4$  means hydrogen,  $C_1$ - $C_{10}$  alkyl, aryl,  $C_7$ - $C_{20}$  aralkyl,

$R^5$  means hydrogen,  $C_1$ - $C_{10}$  alkyl, aryl,  $C_7$ - $C_{20}$  aralkyl,

wherein, for  $R^4$  and  $R^5$ , aryl is phenyl, ~~which are wherein said phenyl is~~ optionally substituted in one or more places by halogen, OH, O-alkyl,  $CO_2H$ ,  $CO_2$ -alkyl, -NH<sub>2</sub>, -NO<sub>2</sub>, -N<sub>3</sub>, -CN,  $C_1$ - $C_{20}$  alkyl,  $C_1$ - $C_{20}$  acyl and/or  $C_1$ - $C_{20}$  acyloxy groups, and

wherein, for  $R^4$  and  $R^5$ , aralkyl is benzyl, ~~or phenylethyl, which are wherein said benzyl, or phenylethyl is~~ optionally substituted in one or more places by halogen, OH, O-alkyl,  $CO_2H$ ,  $CO_2$ -alkyl, -NO<sub>2</sub>, -N<sub>3</sub>, -CN,  $C_1$ - $C_{20}$  alkyl,  $C_1$ - $C_{20}$  acyl and/or  $C_1$ - $C_{20}$  acyloxy groups,

$R^6$ ,  $R^7$  each mean a hydrogen atom, or together mean an additional bond to result in a double bond on the ring between their two positions or together mean an oxygen atom to provide an epoxide ring,

$R^8$  means a methyl group or hydrogen,

and at the same time,  $R^{1a}$  and  $R^{1b}$  together stand for a trimethylene group,  $R^2$  stands for a phenyl or benzyl radical, and X stands for a 2-pyridyl, 2-methyl-4-thiazolyl or 2-methyl-4-oxazolyl radical or

at the same time  $R^{1a}$  and  $R^{1b}$  together stand for a trimethylene group,  $R^2$  stands for a methyl, ethyl or propyl group and X stands for a 2-pyridyl, 2-methyl-4-thiazolyl or 2-methyl-4-oxazolyl radical or

at the same time  $R^{1a}$  and  $R^{1b}$  in each case stand for a methyl group,  $R^2$  stands for a methyl, ethyl or propyl radical, and X stands for a 2-pyridyl, 2-methyl-4-thiazolyl or 2-methyl-4-oxazolyl radical,

whereby the nitrogen atom and/or the sulfur atom in X can be present in oxidized form, and whereby, if  $R^2$  and  $R^8$  in each case mean a methyl radical, X can be only one 2-pyridyl radical that is optionally oxidized on the nitrogen atom,  
including all possible stereoisomers or a stereoisomer thereof.

2. **(Previously presented)** A compound according to claim 1, in which  $R^8$  is a hydrogen atom.

3. **(Previously presented)** A compound according to claim 1, in which  $R^8$  is a methyl group.

4. **(Previously presented)** A compound according to claim 1, in which  $R^2$  is an ethyl group.

5. **(Previously presented)** A compound according to claim 1, in which  $R^2$  is a propyl group.

6. **(Previously presented)** A compound according to claim 2, in which  $R^{1a}$  and  $R^{1b}$  together mean a trimethylene group.

7. **(Previously presented)** A compound according to claim 3, in which  $R^{1a}$  and  $R^{1b}$  together mean a trimethylene group.

8. **(Previously presented)** A compound according to claim 6, in which X means a 2-pyridyl radical that is oxidized on the nitrogen atom.

9. **(Previously presented)** A compound according to claim 7, in which X means a 2-pyridyl radical that is oxidized on the nitrogen atom.

10. **(Previously presented)** A compound according to claim 2, in which X means a 2-pyridyl radical that is optionally oxidized on the nitrogen atom.

11. **(Previously presented)** A compound according to claim 4, in which  $R^{1a}$  and  $R^{1b}$  together mean a trimethylene group.

12. **(Previously presented)** A compound according to claim 5, in which  $R^{1a}$  and  $R^{1b}$  together mean a trimethylene group.

13. **(Previously presented)** A compound according to claim 11, in which X means a 2-pyridyl radical that is optionally oxidized on the nitrogen atom.

14. **(Previously presented)** A compound according to claim 12, in which X means a 2-pyridyl radical that is optionally oxidized on the nitrogen atom.

15. **(Previously presented)** A compound according to claim 2, in which  $R^2$  means an ethyl group,  $R^{1a}$  and  $R^{1b}$  together mean a trimethylene group and X means a 2-pyridyl radical that is optionally oxidized on the nitrogen atom.

16. **(Previously presented)** A compound according to claim 2, in which  $R^2$  means a propyl group,  $R^{1a}$  and  $R^{1b}$  together mean a trimethylene group, and X means a 2-pyridyl radical that is optionally oxidized on the nitrogen atom.

17. **(Previously presented)** A compound according to claim 10, in which  $R^2$  is a propyl group.

18. **(Previously presented)** A compound according to claim 1, in which  $R^5$  is a methyl group.

19. **(Previously presented)** A compound according to claim 1, in which R<sup>1a</sup> and R<sup>1b</sup> in each case stand for a methyl group and R<sup>2</sup> stands for a methyl or propyl group.

20. **(Previously presented)** A compound of formula I, of claim 1, which is:  
(4S,7R,8S,9S,13(E or Z),16S(E))-4,8-Dihydroxy-16-(2-(2-methyl-4-thiazolyl)ethenyl)-1-oxa-5,5,7,9,13-pentamethyl-cyclohexadec-13-ene-2,6-dione,  
(1(S or R),3S(E),7S,10R,11S,12S,16R)-7,11-Dihydroxy-3-(2-(2-methyl-4-thiazolyl)ethenyl)-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadeca-5,9-dione,  
(1(R or S),3S(E),7S,10R,11S,12S,16S)-7,11-Dihydroxy-3-(2-(2-methyl-4-thiazolyl)ethenyl)-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadeca-5,9-dione,  
(4S,7R,8S,9S,13(E or Z),16S(E))-4,8-Dihydroxy-7-ethyl-16-(2-(2-methyl-4-thiazolyl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-cyclohexadec-13-ene-2,6-dione,  
(1(S or R),3S(E),7S,10R,11S,12S,16R)-7,11-Dihydroxy-10-ethyl-3-(2-(2-methyl-4-thiazolyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadeca-5,9-dione,  
(1(R or S),3S(E),7S,10R,11S,12S,16S)-7,11-Dihydroxy-10-ethyl-3-(2-(2-methyl-4-thiazolyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadeca-5,9-dione,  
(4S,7R,8S,9S,13(E or Z),16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa-5,5-(1,3-trimethylene)-7,9,13-trimethyl-cyclohexadec-13-ene-2,6-dione,  
(1(S or R),3S(E),7S,10R,11S,12S,16R)-7,11-Dihydroxy-3-(1-methyl-2-(2-pyridyl)ethenyl)-8,8-(1,3-trimethylene)-10,12,16-trimethyl-4,17-dioxabicyclo[14.1.0]heptadeca-5,9-dione,  
(1(R or S),3S(E),7S,10R,11S,12S,16S)-7,11-Dihydroxy-3-(1-methyl-2-(2-pyridyl)ethenyl)-8,8-(1,3-trimethylene)-10,12,16-trimethyl-4,17-dioxabicyclo[14.1.0]heptadeca-5,9-dione,

(4S,7R,8S,9S,13(E or Z),16S(E))-4,8-Dihydroxy-16-(2-(2-methyl-4-thiazolyl)ethenyl)-1-oxa-5,5-(1,3-trimethylene)-7,9,13-trimethyl-cyclohexadec-13-ene-2,6-dione,

(1(S or R),3S(E),7S,10R,11S,12S,16R)-7,11-Dihydroxy-3-(2-(2-methyl-4-thiazolyl)ethenyl)-8,8-(1,3-trimethylene)-10,12,16-trimethyl-4,17-dioxabicyclo[14.1.0]heptadeca-5,9-dione,

(1(R or S),3S(E),7S,10R,11S,12S,16S)-7,11-Dihydroxy-3-(2-(2-methyl-4-thiazolyl)ethenyl)-8,8-(1,3-trimethylene)-10,12,16-trimethyl-4,17-dioxabicyclo[14.1.0]heptadeca-5,9-dione,

(4S,7R,8S,9S,13(E or Z),16S(E))-4,8-Dihydroxy-16-(2-(2-pyridyl)ethenyl)-1-oxa-5,5,7,9,13-pentamethyl-cyclohexadec-13-ene-2,6-dione,

(1(S or R),3S(E),7S,10R,11S,12S,16R)-7,11-Dihydroxy-3-(2-(2-pyridyl)ethenyl)-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadeca-5,9-dione,

(1(R or S),3S(E),7S,10R,11S,12S,16S)-7,11-Dihydroxy-3-(2-(2-pyridyl)ethenyl)-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadeca-5,9-dione,

(4S,7R,8S,9S,13(E or Z),16S(E))-4,8-Dihydroxy-7-ethyl-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa-5,5-(1,3-trimethylene)-9,13-dimethyl-cyclohexadec-13-ene-2,6-dione,

(1(S or R),3S(E),7S,10R,11S,12S,16R)-7,11-Dihydroxy-10-ethyl-3-(1-methyl-2-(2-pyridyl)ethenyl)-8,8-(1,3-trimethylene)-12,16-dimethyl-4,17-dioxabicyclo[14.1.0]heptadeca-5,9-dione,

(1(R or S),3S(E),7S,10R,11S,12S,16S)-7,11-Dihydroxy-10-ethyl-3-(1-methyl-2-(2-pyridyl)ethenyl)-8,8-(1,3-trimethylene)-12,16-dimethyl-4,17-dioxabicyclo[14.1.0]heptadeca-5,9-dione,

(4S,7R,8S,9S,13(E or Z),16S(E))-4,8-Dihydroxy-7-ethyl-16-(2-(2-methyl-4-thiazolyl)ethenyl)-1-oxa-5,5-(1,3-trimethylene)-9,13-dimethyl-cyclohexadec-13-ene-2,6-dione,

(1(S or R),3S(E),7S,10R,11S,12S,16R)-7,11-Dihydroxy-10-ethyl-3-(2-(2-methyl-4-thiazolyl)ethenyl)-8,8-(1,3-trimethylene)-12,16-dimethyl-4,17-dioxabicyclo[14.1.0]heptadeca-5,9-dione,

(1(R or S),3S(E),7S,10R,11S,12S,16S)-7,11-Dihydroxy-10-ethyl-3-(2-(2-methyl-4-thiazolyl)ethenyl)-8,8-(1,3-trimethylene)-12,16-dimethyl-4,17-dioxabicyclo[14.1.0]heptadeca-5,9-dione,

(4S,7R,8S,9S,13(E or Z),16S(E))-4,8-Dihydroxy-7-ethyl-16-(2-(2-pyridyl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-cyclohexadec-13-ene-2,6-dione,

(1(S or R),3S(E),7S,10R,11S,12S,16R)-7,11-Dihydroxy-10-ethyl-3-(2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadeca-5,9-dione,

(1(R or S),3S(E),7S,10R,11S,12S,16S)-7,11-Dihydroxy-10-ethyl-3-(2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadeca-5,9-dione,

(4S,7R,8S,9S,13(E or Z),16S(E))-4,8-Dihydroxy-7-ethyl-16-(2-(2-pyridyl)ethenyl)-1-oxa-5,5-(1,3-trimethylene)-9,13-dimethyl-cyclohexadec-13-ene-2,6-dione,

(1(S or R),3S(E),7S,10R,11S,12S,16R)-7,11-Dihydroxy-10-ethyl-3-(2-(2-pyridyl)ethenyl)-8,8-(1,3-trimethylene)-12,16-dimethyl-4,17-dioxabicyclo[14.1.0]heptadeca-5,9-dione,

(1(R or S),3S(E),7S,10R,11S,12S,16S)-7,11-Dihydroxy-10-ethyl-3-(2-(2-pyridyl)ethenyl)-8,8-(1,3-trimethylene)-12,16-dimethyl-4,17-dioxabicyclo[14.1.0]heptadeca-5,9-dione,

(4S,7R,8S,9S,13Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa-7-propyl-5,5,9,13-tetramethyl-cyclohexadec-13-ene-2,6-dione,

(1S,3S(E),7S,10R,11S,12S,16R)-10-Propyl-7,11-dihydroxy-3-(1-methyl-2-(2-N-oxidopyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[4.1.0]heptadeca-5,9-dione,

(1R,3S(E),7S,10R,11S,12S,16S)-10-Propyl-7,11-dihydroxy-3-(1-methyl-2-(2-N-oxidopyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[4.1.0]heptadeca-5,9-dione,

(1S,3S(E),7S,10R,11S,12S,16R)-10-Propyl-7,11-dihydroxy-3-(1-methyl-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[4.1.0]heptadeca-5,9-dione,

(1R,3S(E),7S,10R,11S,12S,16S)-10-Propyl-7,11-dihydroxy-3-(1-methyl-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[4.1.0]heptadecane-5,9-dione,

(4S,7R,8S,9S,13E,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa-7-propyl-5,5,9,13-tetramethyl-cyclohexadec-13-ene-2,6-dione,

(1R,3S(E),7S,10R,11S,12S,16R)-10-Propyl-7,11-dihydroxy-3-(1-methyl-2-(2-N-oxidopyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[4.1.0]heptadeca-5,9-dione,

(1S,3S(E),7S,10R,11S,12S,16S)-10-Propyl-7,11-dihydroxy-3-(1-methyl-2-(2-N-oxidopyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[4.1.0]heptadeca-5,9-dione,

(1R,3S(E),7S,10R,11S,12S,16R)-10-Propyl-7,11-dihydroxy-3-(1-methyl-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[4.1.0]heptadeca-5,9-dione, or

(1S,3S(E),7S,10R,11S,12S,16S)-10-Propyl-7,11-dihydroxy-3-(1-methyl-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[4.1.0]heptadeca-5,9-dione.

21. **(Previously presented)** A pharmaceutical composition comprising at least one compound of formula I according to claim 1 above as well as a pharmaceutically compatible vehicle.

22. (Canceled)

23. (Previously presented) A method for preparing a pharmaceutical agent which comprises formulating a compound of formula I according to claim 1 in a form suitable for pharmaceutical administration.